Hydrogel Microtube Drug Carrier for Catheter‐Based Intravascular Therapy Authors: Shota Sato, Hiroki Ohta, Naoki Takakura, Kentaro Kasa, Teppei Komatsu, Dai Kejia, Misato Yoshioka, Hirotaka James Okano, Hiroaki Onoe Published: 2026 ABSTRACT ABSTRACTThis paper proposes the hydrogel microtube carrier that can be retained within blood vessels without interrupting blood flow for the practical application of intravascular therapy. The stable three‐dimensional network formed by the barium alginate gel enables the carrier to retain drugs within blood vessels. The utility of this hydrogel microtube carrier was confirmed through in vitro vascular mimic models and in vivo rat experiments. These experiments demonstrated that the hydrogel microtube carrier can be retained within blood vessels without obstructing blood flow and can deliver the drug model, Lipiodol, in the small renal artery. The hydrogel microtube carrier we propose represents a potential new platform advancing the practical application of intravascular drug delivery systems (DDS) and intravascular cell therapy. Introduction Drug delivery systems (DDS) have been a breakthrough technology enabling localized drug delivery [1, 2] to treat a wide range of diseases and promote health [3]. Recently, to enable more accurate treatment, multi‐scale and multi‐material DDS that combines different materials at different scales, such as microscale carriers and nanoscale drugs, have been intensively studied [4]. Those multiscale and multi‐material DDS, such as a mixture of biocompatible polymers with different particle designs [5] or a hydrogel containing both drugs and release‐controlled agents [6, 7, 8, 9], provide benefits to reduce dosing frequency and simplify its administration. In particular, hydrogels are natural materials with superior biocompatibility and biodegradability [10, 11], leading to suitable materials as carriers for DDS. Hydrogel DDS has shown high drug uptake efficiency [11], and can be engineered to provide responsiveness to external stimuli [12] such as pH [13], temperature [14], magnetic field [15], and enzymatic degradability [16]. As for delivery methods, those hydrogel DDS have been applied to various target diseased organs with intravenous injections [17] and subcutaneous injections [18]. From the point of view of delivery methods, the ability to stably fix the DDS carrier is one of the important functions required of the DDS carrier. Especially, blood vessels is circulation system that almost all organs possess and is important target for enabling DDS to function [19, 20]. On the other hand, previously reported hydrogel DDS have faced challenges in fixing the DDS in blood vessels to maintain drug release for a specific term because continuous blood flow tends to flush out the DDS carriers. Therefore, as the carriers for DDS, optimization of the size and shape of the hydrogel carrier to be stably fixed in blood vessels has been researched. One of the promising approaches involves using a fiber‐shaped carrier for DDS. The shape of the fiber has advantages to be easily fixed in blood vessels due to the shape being thin like blood vessels. Furthermore, a fiber‐shaped DDS carrier is suitable for handling with a catheter for injection. Previous studies have reported that pH‐responsive nanocore‐shell fibers encapsulated with anticancer drugs showed efficacy against colorectal cancer [21], and that intravenous injection of two‐layered hydrogel microfibers encapsulated with mesenchymal stem cells recovered renal function [22]. However, those fiber‐shaped DDS carriers had an inevitable risk of causing embolism in blood vessels during the drug delivery, resulting in adverse ischemic effects. Thus, fiber‐shaped intravascular DDS have required improved design without interrupting blood flow. In this paper, we propose a hydrogel microtube carrier that can be retained within blood vessels without interrupting blood flow (Figure 1a,b). This hydrogel microtube carrier is made of biocompatible barium alginate hydrogel that is stable in blood flow by a tightly bound three‐dimensional (3D) polymer network [23]. This tubular hydrogel carrier can be delivered into blood vessels using a catheter, allowing for minimally invasive delivery to the target site. We have targeted small arteries (300–400 µm) as the target vessels for delivering our microtube carriers. In this paper, we demonstrate how to deliver the carriers to renal vessels in rats. The catheter delivers the hydrogel microtube carriers one by one, allowing for selective and targeted delivery (Figure 1c). After delivery of the microtube carrier, the encapsulated drug is released and shows effects in the surrounding tissues. In this study, hydrogel microtube carriers were fabricated using a two‐layered co‐axial microfluidic device. The fabricated hydrogel microtube carriers were evaluated by using an in vitro vascular model and rat renal artery to confirm their stable fixation in the blood vessel and blood flow passage without interruption. Concept of our hydrogel microtube carrier. (a) Hydrogel microtube carrier that can be delivered with a catheter. (b) Cross‐sectional view of the hydrogel microtube carrier. (c) Schematic illustration of the delivery method for the hydrogel microtube carrier that does not block the blood flow after fixation. Theory In designing the hydrogel microtube carrier, the length of the microtube carrier, l, and the inner diameter of the microtube carrier, b, were theoretically considered. When the hydrogel microtube carrier is delivered and retained in a blood vessel, blood flow passes through the hydrogel microtube carrier. In this case, because the cross‐sectional area of the blood flow decreases due to the hydrogel microtube carrier, fluid resistance to blood flow increases, and the original volumetric flow rate of the blood flow decreases. When the volumetric flow rate of the blood flow drastically decreases by the microtube carrier, the surrounding tissues may become ischemic due to insufficient blood supply. Therefore, it is necessary to design the microtube carrier with an optimal hollow cross‐sectional area and length to ensure sufficient blood supply. In our model, the blood flow within vessels was assumed as Hagen–Poiseuille flow, which has been widely utilized in previous studies (Figure 2a) [24, 25]. In Hagen–Poiseuille flow, the blood volume flow rate, Qnormal , is defined by Equation (1) as follows: where a is the vessel radius, η is the blood viscosity, L is the length of the targeted vessel, and ΔP is the pressure difference across the blood vessel, (1) Qnormal=πa48ηLΔP. Design theory of hydrogel microtube carriers. (a) Vascular model before delivery of the hydrogel microtube carrier. (b) Vascular model after delivery of the hydrogel microtube carrier. (c) Three‐dimensional curved surface graph for designing the hydrogel microtube carrier. The relationship between blood supply volumetric flow rate, Qtube /Qnormal , hollow ratio, ϕ, and tube length ratio, λ. The green plane represents Qtube / Qnormal = 0.25; Qtube / Qnormal = 0.25 or lower cause ischemia. Thus, the fluid resistance of the target vessel, Rnormal , is defined as, (2) Rnormal=8ηLπa4. By using the Equation (1) and (2), the blood volume flow rate, Qnormal , was expressed as, (3) Qnormal=ΔPRnormal. When the hydrogel microtube carrier is delivered (Figure 2b), the model can be considered as a composition of two parts: the section (i) where the hydrogel microtube carrier is retained and sections (ii) that are not. Therefore, after the delivery of the hydrogel microtube into the blood vessels, the fluid resistance, Rtube , and blood volume flow rate Qtube are expressed by Equations (4) and (5), defined as follows: (4) Rtube=Ri+Rii=8ηL−lπa4+8ηLπb4, (5) Qtube=ΔPRtube, where l is the length of the hydrogel microtube carrier, and b is the radius of the hollow core, R (i), R (ii). In this design, the pressure differences, ΔP, in Figure 2a,b are considered to be constant due to the heart's pumping function, even when the hydrogel microtube carrier is retained within the blood vessel. Consequently, the ratio of blood volume flow delivered by the hydrogel microtube carrier, Qtube /Qnormal , is obtained as (6) QtubeQnormal=ΔPRtubeΔPRnormal=RnormalRtube=La4L−la4+lb4. We define dimensionless numbers, the hollow ratio, ϕ, and the length ratio of the targeted blood vessel to the microtube carrier, λ, as (7) ϕ=ba, (8) λ=lL. By using these Equations (7) and (8), Qtube /Qnormal can be expressed as, (9) QtubeQnormal=11−λ+λϕ4· Assuming that our hydrogel microtube carrier is delivered to the arterioles and capillaries, we set a = 0.15 mm and L = 10 mm. By calculating b and l as variable parameters, a 3D curved surface graph was obtained (Figure 2c). It is generally known that when blood flow, Qtube /Qnormal , decreased to approximately 0.25 or less, the risk of tissue and organ necrosis increases significantly [26]. Therefore, the hollow ratio, ϕ, needs to be designed to ensure that Qtube /Qnormal approximately does not fall below 0.25. From this fact, the curved surface over the plane of Qtube / Qnormal = 0.25 represents the optimal design parameters, b and l, for the microtube carrier. In this study, we fabricated hydrogel microtube carriers by selecting parameters λ = 1.00 (b = 0.11 mm), ϕ=0.74(l=10mm), and Qtube /Qnormal = 0.30. Result Fabrication of Hydrogel Microtubes Hydrogel microtubes were fabricated with two‐layered co‐axial laminar‐flow microfluidic devices (Figure 3a,b), assembled with round glass capillaries, square glass capillaries, connectors fabricated by a 3D printer, and a slide glass. By flowing core solution (3% (w/w) fluid‐state polyethylene oxide (PEO)), shell solution (1.5% (w/v) sodium alginate pre‐gel solution), and cross‐linking agent (100 mm barium chloride) through these three inlets in the co‐axial microfluidic device, barium‐alginate hydrogel microtubes can be continuously fabricated (Figure 3c). The fabricated microtube was cut into ∼10 mm‐length pieces with scissors. In order to remove the PEO in the core, the cut microtubes were shaken in storage solution (described in the Experimental Section) in an incubator overnight (Figure 3d) to obtain hydrogel microtube carriers. To visualize the hollow structure of hydrogel microtube carriers, red and green fluorescent polystyrene beads (diameter: 200 nm) were mixed in the PEO core and the sodium alginate shell, respectively. Fabrication method for hydrogel microtube carriers. (a) Cross‐sectional view of the two‐layered coaxial laminar‐flow microfluidic device. (b) Image of the two‐layered coaxial microfluidic device. (c) Schematic diagram of hydrogel microtube fabrication (d) Rinsing procedure of PEO in the microtube to obtain the hydrogel microtube carrier. The fluorescence images of the fabricated microtubules confirm that the core‐shell structure was formed by varying the core flow ratio, Qcore /(Qcore + Qshell ), from 1:2 to 2:1 (the total flow rate: 300 µL/min) (Figure 4a). From these fluorescence images, the diameters of the core and shell were evaluated (Figure 4b). When the core flow ratio increased to 0.10, 0.25, and 0.44, the ratio of the hollow diameter of the microtube, b/a, increased to 0.50, 0.74, and 0.91. These results show that the diameter can be controlled by manipulating the core flow ratio. As described in the theory section, to ensure sufficient blood flow, the hollow ratio must be over 0.70 when the microtube length is 10 mm. This requirement is satisfied by conditions (ii) and (iii). Since our hydrogel microtubes, retained intra‐vascularly, also require a certain degree of mechanical strength to prevent collapse in the bloodstream, the hydrogel microtubes were thereafter fabricated under the conditions (ii). Evaluation of fabricated hydrogel microtubes. (a)Fluorescence images of hydrogel microtubes (green: barium alginate gel, red: PEO). (b) Relationship between flow rate and diameter (n = 12 from three independent samples, mean ± s.d.). (c) Changes in fluorescence intensity over shaking time (n = 4, mean ± s.d. The linear mixed model indicated that the differences of fluorescent intensities for the shell and core have a significant, ***p < 0.001, p = 1.43 × 10− 1 2). (d) Diagram of confocal microscopy imaging of hydrogel microtubes. (e) The Z‐stack image and reconstructed, y‐z cross‐section (All scale bars: 400 µm). After cutting and shaking the hydrogel microtube, we measured the fluorescence intensity values of each core and shell region with a fluorescence microscope (Figure 4c). While the fluorescence intensity of the shell region remained nearly constant, that of the core region decreased. The linear mixed‐effects model between these shell and core regions revealed a significant difference (***p < 0.001) after 16 hour‐shaking, indicating the PEO in the microtube was rinsed. Furthermore, the cross‐sectional image obtained by confocal fluorescence microscopy reveals that the red fluorescent signal of the PEO solution was almost removed in the core region of the hydrogel microtube carriers (Figure 4d,e). In these results, we confirmed that hollow barium alginate hydrogel microtube carriers were formed by removing the PEO solution in the core. Experiment of Hydrogel Microtube Carrier Delivery Using the In Vitro Vascular Mimic Model To confirm whether the hydrogel microtubes we fabricated can be retained within blood vessels, we conducted microtube delivery experiments using the in vitro vascular mimic model (Figure 5a,b). The in vitro vascular mimic model was fabricated using PDMS (polydimethylsiloxane) by molding and designed to mimic the shape of the small arteries and capillaries, where the microtube carrier is delivered in vivo. The inlet width of the horseshoe‐shape microchannel is 0.8 mm, and the stenotic region has a width of 0.3 mm. The hydrogel microtube carrier was delivered to the fabricated in vitro vascular mimic model and fixed at the stenotic region. In this experiment, given the flow velocity, U = 1.2 × 10−3 m/s, the kinematic viscosity coefficient, ν = 1.0 × 10−6 m 2/s, and the flow path radius, r = 1.5 × 10−4 m, the Reynolds number, Re, can be calculated as follows: Re=1.2×10−3×2×1.5×10−41.0×10−6≅0.36<1. Conceptual diagram of the fabricated in vitro vascular mimic model. (a) Overall view, (b) x–z cross‐sectional view. (c) y–z cross‐sectional view of the in vitro vascular mimic model in microtube carrier delivery experiments. Since the Reynolds number calculated is within the laminar flow range, this experiment was conducted under laminar flow conditions. After that, tracer microbeads (green fluorescent polystyrene beads, 10 µm in diameter) were flowed into an in vitro vascular mimic model to visualize the flow inside the hydrogel microtube carrier (Figure 5c). The fluorescence observation confirmed that the fluorescent beads flowed inside the hydrogel microtube carrier fixed in an in vitro vascular mimic model (Figure 6a,b), Movie S1 and Figure S1). This result indicates that our microtube carriers can be fixed to blood vessels, and blood flow passes through the microtube carriers without interrupting blood circulation. Results of microtube carrier delivery in an in vitro vascular mimic model. (a) Phase‐contrast image of delivered hydrogel microtube carrier. (b) Sequential images of fluorescent beads (green, 0.2 µm in diameter) during flow (t (s): Elapsed time of bead flow) (All scale bars: 500 µm). Fabrication of Hydrogel Microtubes Encapsulated With Drug Model As a DDS application of the hydrogel microtube carriers, we fabricated hydrogel microtube carriers encapsulating a drug model. As the drug model, one possible candidate is Lipiodol, which is used in TACE (trans arterial chemoembolization) treatment for hepatocellular carcinoma [27] and in radiation therapy for lymph nodes [28] in clinical settings. In addition, Lipiodol works as a contrast agent for angiography. Therefore, in this study, Lipiodol was adopted to simultaneously confirm drug‐carrying and visualization by X‐ray angiography of the hydrogel microtube carrier. To demonstrate the drug retaining capability of our proposed hydrogel microtube carrier, Lipiodol was mixed in the barium hydrogel shell at 40%–50% with emulsification (Figure 7a). X‐ray irradiation observation showed a cross‐sectional image with a hollow core. This result means that Lipiodol was entrapped in the shell layer and can be visualized by X‐rays (Figure 7b,c,d). Evaluation of hydrogel microtubes containing Lipiodol. (a) Phase‐contrast image of the hydrogel microtube containing Lipiodol. (b) X‐ray irradiation image of a hydrogel microtube. (c) Cross‐sectional view of X‐ray irradiation image. (d) Graph of measured gray values from the cross‐sectional X‐ray image (n = 7, average) ((a) Scale bar: 200 µm, (b) Scale bar: 10 mm, (c) Scale bar: 1 mm). Experiment of In Vivo Microtube Carrier Delivery Using Rats To confirm efficacy in vivo, we conducted an in vivo experiment delivering the hydrogel microtube carrier encapsulating Lipiodol into rat renal blood vessels. Delivery of the hydrogel microtube carrier to the rat renal artery was conducted by the “Ohta method” with a catheter [29]. Hydrogel microtube carriers encapsulating Lipiodol were cut to a length of 5 mm and filled into the catheter. The catheter was cannulated from the caudal artery to the renal artery. After that, the hydrogel microtube carrier was ejected into the renal arteries for fixing (Figure 8a and Movie S2). Then, to visualize blood flow around the fixed microtube carrier, a contrast agent was injected into the arteries in the rat kidney. The sequential images of the digital subtraction angiography (DSA) confirm that the contrast agent passes through the microtube carrier and that the blood flow reaches the peripheral arteries of the rat kidney (Figure 8b and Movie S3). In another case, the delivered hydrogel microtube carrier was retained for 4 days, and the follow‐up observation was conducted. First, on day 0, the hydrogel microtube carrier was retained in the target vessel. Then, on day 4, angiography was performed again on the rat kidney to confirm blood flow (Figure 9a,b). The narrowed blood flow in the section where the hydrogel microtube carrier was fixed (Figure 9c, green square) confirmed that the hydrogel microtube carrier is continuously retained. The peripheral blood vessel (Figure 9c, red dotted line) from the fixed section of the hydrogel microtube carrier was also confirmed to contain flowing blood. In addition, the kidney that delivered the hydrogel microtube carrier was excised, and the internal structure of the hydrogel microtube carrier was confirmed using an X‐ray irradiation equipment (Figure 9d). The hydrogel microtube carrier was confirmed to maintain the hollow structure that is comparable to that of the fabricated hydrogel microtube carrier in Figure 7c. Based on these results, our hydrogel microtube carrier can be maintained within blood vessels in vivo without obstructing blood flow. In vivo delivery experiment of the hydrogel microtube carriers encapsulating Lipiodol to the rat artery. (a) X‐ray contrast image of the delivered hydrogel microtube carrier. (b)Sequential differential images of contrast agent injection after the delivery of hydrogel microtube carrier (contrast agent flow sequence: (1)(2)(3)(4), arrows indicate contrast agent) ((a)(b) scale bars: 10 mm, (b) enlarged image scale bar: 200 µm). X‐ray contrast imaging showing the delivery and follow‐up of Lipiodol‐containing hydrogel microtube carriers to the rat kidney. (a) X‐ray contrast image of the rat kidney before hydrogel microtube carrier delivery, (b) X‐ray contrast images (with digital subtraction angiography (DSA) processing) upon delivery of hydrogel microtube carriers, (c) X‐ray contrast imaging performed on the rat kidney on day 4, (d) X‐ray CT images of the rat kidney implanted with hydrogel microtube carriers on day 4 ((a)(b)(c) Scale bar: 5 mm, (d) Scale bar: 1 mm). Discussion In this paper, we proposed hydrogel microtube carriers composed of barium alginate gel and confirmed their utility as novel hydrogel carriers for intravascular DDS in both in vitro (Figure 6) and in vivo (Figure 8) environments. In conventional intravascular DDS, there was a risk of causing ischemia due to blood flow obstruction by embolizing the vascular region where the hydrogel carrier was placed [21, 22, 30]. The proposed hydrogel microtube carrier in this study enables retention in blood vessels while ensuring blood flow. The microtube carrier fabricated in this paper is designed to occupy 0.25 of the vascular cross‐sections. This design was confirmed to remain in the microtube carriers retained within rat renal vessels (Figure 8). In the case of humans, we can expect that the inner diameter of the tube carrier could be larger while keeping the thickness of the tube carrier, enabling the increase of cross‐sectional area of the blood flow path sufficiently. This modification contributes to the increase of the blood flow to reduce the risk of unintended results in the surrounding tissues. Based on these issues, careful consideration would be required regarding the actual blood supply after delivering the microtube carrier. Additionally, in the case of using microtubes for other animals, such as humans, the outer and inner diameters of the microtube carrier are adjustable by the flow rates of the core and shell solution and by the modification of the devices [30, 31, 32, 33, 34]. Therefore, our microtube carrier can be tuned to match a wide range of blood vessel diameters in vivo. Furthermore, the catheter‐based delivery system used in this study enables precise delivery of individual microtube carriers to targeted areas, allowing for selective delivery to blood vessels. Since both blood vessels and microtube carriers possess elasticity, allowing the delivered microtube carrier can fit the shape of the vessel wall. Therefore, the system we propose is highly valuable as an intravascular DDS carrier that can be retained while ensuring blood flow within the body. In this paper, we conducted experiments using Lipiodol as a drug model for intravascular DDS (Figure 7, 8). Lipiodol is biocompatible and has clinical applications such as treatment of hepatocellular carcinoma (TACE) and as a drug carrier [27, 35, 36]. Also, its main component is iodine, with high radiopaque properties, and it is clinically used as a contrast agent [28, 37]. Thus, X‐ray observation revealed that the microtube carrier can retain the encapsulated drugs in vivo blood vessels (Figure 8). On the other hand, although this result confirms the retention of Lipiodol, it does not verify sustained release. We have not investigated drug release from the tubular alginate microcarriers proposed in this paper. However, previous research has confirmed drug release from alginate gels. Delivery of barium alginate gel microfibers encapsulating mesenchymal stem cells (MSCs) to blood vessels in rat kidneys has been reported to recover renal function due to cytokines released by MSCs [22]. In addition, drug release testing of methotrexate from barium alginate gel has also been demonstrated as bead‐shaped carrier [36]. Furthermore, gene delivery into mouse gluteal muscles by encapsulating adeno‐associated virus in calcium alginate gel has been reported [37]. Based on the results of previous research, our proposed microtube carrier can be used to encapsulate drugs, enabling drug release. Additionally, the potential for intravascular therapy with hydrogel carriers was also demonstrated by an evaluation of renal function using hydrogel carriers encapsulating mesenchymal stem cells (Figure S3). In addition, by confirming sustained release with other drugs, the potential as a DDS carrier can be further expanded. For example, protein drugs with high target specificity and low side effects, such as chitosan, poly‐lactic acid, and polylactic‐co‐glycolic acid, can be applied in immunotherapy and molecular targeted therapy [38, 39]. Moreover, gene therapy can be performed using adeno‐associated virus vectors, a non‐pathogenic viral vector [40, 41, 42]. By encapsulating these within the hydrogel microtube carriers fabricated in this study, we hope to enable the clinical application of an intravascular DDS. The hydrogel microtube carrier fabricated in this study can be used as a carrier for long‐term retention within the body. Our hydrogel microtube carrier has been confirmed to remain stably implanted in vivo for 4 days (Figure 9) and maintain shape for 6 days (Information S2). Considering utilization as a future DDS carrier, we expect that our hydrogel microtube carrier will be capable of sustaining drug release for approximately 1 week. Since the possibility of collapse of our microtube carrier by degradation due to long‐term retention remains, it would be our future challenge to maintain the safety to avoid relocation/clog of the degraded carrier in the blood vessel. In this study, to maintain the mechanical strength of the carrier within the bloodstream, we fabricated a microtube carrier composed of barium alginate gel. If a hydrogel microcarrier could be fabricated from another biodegradable material that can withstand blood flow, it could enhance its utility as a DDS carrier. For instance, a biodegradable hydrogel that can withstand blood flow and can gradually dissolve after treatment [43], or a biocompatible hydrogel that dissolves selectively after treatment [44]. In any case, hydrogels that can be safely used within the bloodstream still require further research [45]. Our in vivo experiment was demonstrated by using rat kidneys (Figure 8), but it is considered that the application can be extended to other organs such as the brain [46]. Furthermore, not only as a DDS, but also as a carrier for cell therapy, our hydrogel microtube carriers work by encapsulating cells producing soluble factors for paracrine effects, such as stem cells. In particular, cell therapy with mesenchymal stem cells (MSCs) to the tissues around the fixed site has been reported for the treatment of cardiovascular diseases and cerebral ischemic diseases [47, 48, 49, 50]. By combining the hydrogel microtube carriers with drugs and MSCs, our proposed DDS platform could contribute to advancing practical intravascular therapies. Conclusion In this study, we fabricated and evaluated a hydrogel microtube carrier with barium alginate gel. Fluorescence intensity measurements and confocal fluorescence microscopy confirm a hollow structure formed after cutting and shaking the hydrogel microtubes made with microfluidic devices. The hollow structure of the hydrogel microtube carrier was also confirmed in delivery experiments to an in vitro vascular model. In addition, in vivo experiments using rat kidneys showed that the hydrogel microtube carrier can be retained within the body. These results suggest it is a promising system for intravascular therapy. The carrier also has potential for a wide range of clinical applications, including as a delivery system for drugs (DDS) and cell therapy. Experimental Section Material For fabrication and storage of hydrogel microtubes, sodium alginate (Na‐Alg., 194–13321), barium chloride (BaCl2, 027–00171), and calcium chloride (CaCl2, 038–24985) were purchased from Wako Pure Chemical Industries; polyethylene oxide (PEO, 372781) from Sigma‐Aldrich; sodium chloride (NaCl, 038–24985) from Manac Incorporated. MilliQ water (Merck Millipore) was used for dissolving and adjusting concentrations. Lipiodol (ethyl ester of iodinated poppy‐seed oil fatty acid, 210402), used as the encapsulated drug, was purchased from Guerbet Japan. Observation Setup An inverted fluorescent microscope (Olympus, IX73P1‐22FL/PH) with a charge‐coupled‐device camera (DP73 and cellSens Imaging Software) was used to observe the fabricated hydrogel microtubes. The 3D structure of hydrogel microtubes was observed by using a confocal microscope (Olympus, FV‐3000). Fabrication of Two‐Layered Co‐Axial Laminar‐Flow Microfluidic Devices Hydrogel microtubes were fabricated by using a two‐layered co‐axial laminar‐flow microfluidic device. The device consists of a round glass capillary (OD: 1.0 mm, ID: 0.6 mm, G‐1, NARISHIGE), a square glass capillary (OD: 1.4 mm, ID: 1.0 mm, 8100‐100, VitroCom, NJ, USA), and a plastic connector. Connectors were fabricated with a 3D printer (AGILISTA, Keyence, Osaka, Japan). Glass capillaries and connectors were assembled on a glass slide (Matsunami Glass Industries) and fixed with adhesives. Fabrication of Hydrogel Microtubes To fabricate hydrogel microtubes, the core solution and the shell solution were prepared as 3% (w/w) PEO (SIGMA) and 1.5% (w/v) sodium alginate (Wako), respectively. As a crosslinking agent, 100 mm barium chloride (Wako) was used. For device cleaning, 145 mm sodium chloride solution (Manac) was used. Each solution was installed into a syringe connected to the two‐layered co‐axial laminar‐flow microfluidic device via silicone tubes (LABORAN, 9‐869‐03, 9‐869‐04) and ETFE tubes (VICI JOUR, JR‐T‐082‐M1.5). Each syringe is driven by a lab‐made syringe pump. During the hydrogel microtube fabrication, the tip of the microfluidic device was kept in pure water. The flow rates of the shell solution were 267, 225, and 167 µL/min, and the flow rates of the core solution 33, 75, and 133 µL/min (The total flow ratios were kept constant at 300 µL/min). These flow rates correspond to cross‐sectional area ratios for core‐to‐shell radius ratios of 1:2, 1:1, and 2:1. The flow rate of crosslinking agent was 4000 µL/min. Fabrication of Hydrogel Microtube Carriers To remove the PEO in the core, the fabricated hydrogel microtubes were cut into 10 mm lengths using Vannas scissors (YS‐7105). The cut microtubes (microtube carriers) in a 100‐mm‐diameter dish with 20.8 mL storage solution (20 mL pure water and 0.8 mL 100 mm barium chloride). The dish with the microtube carriers was placed in a shaker (TAITEC,0083717‐000) in an incubator and shaken at 40 rpm for 16 h. After shaking, the solution in the dish was replaced with a new storage solution to remove the remaining PEO. Evaluation of Hydrogel Microtube Carriers The removal of PEO in microtube carriers during the shaking were evalulated by analyzing the changes in fluorescence intensity of the shell and core by using image analysis software (Fiji, an open‐source image processing package). In addition, 3D structure of the hydrogel microtube carriers was observed with the fluorescent confocal microscope (Olympus), and Z‐stack images (series of images at different focal planes) and cross‐sectional views were acquired. Fabrication of the In Vitro Vascular Mimic Model To confirm that hydrogel microtube carriers can be retained within blood vessels, an in vitro blood vessel mimic model was fabricated. First, a convex aluminum mold shaped to mimic the stenosed blood vessel was michined. Next, PDMS (polydimethylsiloxane) (SILPOT184w/c) was poured into it and cured to create a PDMS concave model. The fabricated concave PDMS and a cover glass (C024501) were bonded by air plasma bonding. To prevent unnecessary non‐specific adhesion to the inner surface of the in vitro vascular model, the model's flow channels were coated with a fluororesin coating agent (Fluorosurf, KYOKUTO SHOKAI). Experimental Method of Microtube Carrier Delivery to the In Vitro Vascular Mimic Model The hydrogel microtube carrier was delivered into the fabricated vascular model with a venous cannula (Terumo, SR‐FS2225). Then, a solution of pure water mixed with fluorescent beads (10 µm in diameter, Invitrogen, 2544428) was injected into the vascular model using a syringe pump (kdScientific, 788111). Video recording of the flowing process was performed by using the inverted fluorescent microscope and the camera (Olympus). Fabrication of Hydrogel Microtube Carriers Encapsulating Lipiodol Hydrogel microtubes encapsulated with Lipiodol were also fabricated using the two‐layered co‐axial laminar‐flow microfluidic device as described above. The core solution was 3% (w/w) fluid‐state polyethylene oxide (PEO). The shell solution was an emulsion solution of sodium alginate (Wako) and Lipiodol (Guerbet), where the total volume of 1 mL containing 2% sodium alginate and 40%–50% Lipiodol was agitated by using an ultrasonic homogenizer (Mitsui Electric Seiki, UX‐050) operating at 30% output in the interval mode of 2 seconds on and 3 seconds off while cooling. The cross‐linking agent for sodium alginate was 100 mm barium chloride (Wako). The flow rates of core solution, shell solution, and crosslinking agent were 75 µL/min, 225 µL/min, and 4000 µL/min, respectively. Fabricated hydrogel microtubes encapsulated with Lipiodol were observed using an X‐ray irradiation system (SHIMAZU, S362‐91000‐58) to examine their internal structure and analyzed using image analysis software (Fiji). Animal This study was conducted with the approval of the Animal Care Use Committee of the Jikei University School of Medicine (protocol number: 2019–047C4, 2024‐011). All procedures were performed in accordance with the Fundamental Guidelines for the Proper Conduct of Animal Experiments and Related Activities in Academic Research Institutions, issued by the Japanese Ministry of Education, Culture, Sports, Science, and Technology. Furthermore, this study was conducted in compliance with the ARRIVE guidelines. Male normotensive Sprague‐Dawley rats (9–12 weeks old; body weight 276–499 g on the day of surgery) obtained from Nihon SLC (Japan SLC, Shizuoka, Japan) and housed in temperature‐controlled polycarbonate cages (temperature: 24°C–25°C, relative humidity: 50%–60%) under a 12‐hour light‐dark cycle. All rats had free access to water and a pellet diet (CE‐2, CLEA Japan, Tokyo, Japan). Experimental Methods for In Vivo Microtube Delivery Using Rats The prepared rats for animal experiments were anesthetized with 1%–3% isoflurane with a small animal vaporizer and a facial mask. During surgery, a multi‐panel heater (Vivaria Co., Osaka, Japan) was used to maintain rat body temperature between 36°C and 37.5°C. It is necessary to keep the entire animal warm, including the tail. As we have previously reported [51], in vivo microtube delivery was performed minimally invasively with a catheter utilizing the “Ohta method” [29, 30, 46]. In this approach, cannula insertion into the renal artery is possible with only a puncture of the caudal ventral artery (CVA). After puncturing the rat's caudal ventral artery (CVA) through a 22‐gauge introducer (Terumo, Tokyo, Japan), a microcatheter (outer diameter: 0.54 mm, inner diameter: 0.42 mm, Kaneko Cord, Tokyo, Japan) and a 0.016‐inch guidewire (Toray Medical, Tokyo, Japan) were inserted. Under X‐ray angiography, a microcatheter and guidewire were introduced from the CVA into the abdominal aorta. The guidewire was withdrawn, and contrast medium (Iohexol, Daiichi Sankyo, Tokyo, Japan) was injected to confirm the position of the renal artery. The location of the renal artery branches was identified, and a cannula was inserted into the renal artery before performing selective angiography. A 10 mm‐long thin capillary tube was attached to the needle tip of a 27‐gauge syringe (SS‐010F2713, Terumo, Tokyo, Japan) used for microtube carrier delivery. After confirming the catheter tip is in the optimal position, the microtube carrier is injected through the catheter. This method is also applicable for intracranial vascular access [46] and can function as an arterial blood sampling line [52]. The syringe was filled with DMEM, and the capillary was filled with a microtube carrier measuring 7 mm in length, 400 µm in diameter, and containing 50% (w/w) lipiodol. The capillary was then connected to a catheter inserted into the tail artery. The microtube carrier was delivered by pushing it forward with DMEM. During this process, the position of the microtube carrier was monitored in real time with digital subtraction angiography (DSA). Afterward, the contrast agent was injected again to observe renal vascular flow following microtube carrier delivery. Another case delivered hydrogel microtube carriers to rat kidneys and followed them for 4 days. Hydrogel microtube carriers (5 mm in length) were fabricated with 4% (w/v) sodium alginate and encapsulated with 50% (v/v) Lipiodol. Using the “Ohta method” described above, we inserted a catheter into the rat's tail artery to access the kidney, then performed angiography to observe renal blood flow. We also excised kidneys delivered with hydrogel microtube carriers and fixed these kidneys using 4% Paraformaldehyde. The fixed kidney tissue was observed for internal structure using the X‐ray irradiation system shown in Experimental Section 6.9. Conflicts of Interest The authors declare no conflicts of interest. Supporting information Supporting File 1: adhm71199‐sup‐0004‐SuppMat.pdf. Supporting File 2: adhm71199‐sup‐0001‐Movie1.mp4. Supporting File 3: adhm71199‐sup‐0002‐Movie2.mp4. Supporting File 4: adhm71199‐sup‐0003‐Movie3.mp4.